Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Interventional, Randomized, Double-blind, Parallel-group, Placebo-controlled Study With an Extension Period to Evaluate the Efficacy and Safety of Eptinezumab for the Prevention of Migraine in Patients With Unsuccessful Prior Preventive Treatments

NCT04418765 is registered in ClinicalTrials.gov with H. Lundbeck A/S as lead sponsor.

NCT NCT04418765
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04418765 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Interventional, Randomized, Double-blind, Parallel-group, Placebo-controlled Study With an Extension Period to Evaluate the Efficacy and Safety of Eptinezumab for the Prevention of Migraine in Patients With Unsuccessful Prior Preventive Treatments
Lead sponsor
H. Lundbeck A/S
Phase
Phase 3
Overall status
Completed
Start date
June 1, 2020
Completion date
September 15, 2022
Enrollment
892 (actual)
Sites
138

Conditions

As the registry lists them; a condition with its own page is linked.

migraine